Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: Data from the CASTLE study

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 22, Issue 6, 2010, Pages 677-686

  Malan, Niel ^a   Su, Jun ^b   Mancini, Marco ^b   Yang, Rong ^b   Wirtz, Victoria ^b   Absalon, Judith ^b   McGrath, Donnie ^b  

^a Triple M Research   (South Africa)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

atazanavir; GI tolerability; health related quality of life; HIV 1

Indexed keywords

ATAZANAVIR; EMTRICITABINE; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; TENOFOVIR;

ADULT; AGED; ARTICLE; DIARRHEA; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRRITABLE BOWEL SYNDROME QUALITY OF LIFE SCORE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT OUTCOME; VOMITING;

ADENINE; ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; HIV INFECTIONS; HIV-1; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OLIGOPEPTIDES; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; PYRIDINES; PYRIMIDINONES; QUALITY OF LIFE; QUESTIONNAIRES; RITONAVIR; YOUNG ADULT;

EID: 77953688416     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120903334641     Document Type: Article

References (24)

1. Burgoyne, R.W., & Tan, D.H. (2008). Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): A balancing act. Journal of Antimicrobial Chemotherapy, 61(3), 469-473.
2. Crum, N.F., Riffenburgh, R.H., Wegner, S., Agan, B.K., Tasker, S.A., Spooner, K.M., et al. (2006). Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART(highly active antiretroviral therapy) eras. Journal of Acquired Immune Deficiency Syndrome, 41(2), 194-200.
3. Cunningham, W.E., Shapiro, M.F., Hays, R.D., Dixon, W.J., Visscher, B.R., George, W.L., et al. (1998). Constitutional symptoms and health-related quality of life in patients with symptomatic HIV disease. American Journal of Medicine, 104(2), 129-136.
4. Drossman, D.A., Patrick, D.L., Whitehead, W.E., Toner, B.B., Diamant, N.E., Hu, Y., et al. (2000). Further validation of the IBS-QOL: A disease-specific qualityof-life questionnaire. American Journal of Gastroenterology, 95(4), 999-1007.
5. Eron, J., Jr., Yeni, P., Gathe, J., Jr., Estrada, V., DeJesus, E., Staszewski, S., et al. (2006). The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial. Lancet, 368(9534), 476-482.
6. Gathe, J., da Silva, B., & Loutfy, M. (2008, February 3-6). Study M05-730 primary efficacy results at week 48: Phase 3, randomized, open-label study of lopinavir/ ritonavir tablets once daily vs. twice daily, co-administered with tenofovir and emtricitabine in ARV-naive HIV-1-infected subjects. Presented at 15th Conference on retrovirus and opportunistic infections (CROI), Boston, MA.
7. Gazzard, B., Bernard, A.J., Boffito, M., Churchill, D., Edwards, S., Fisher, N., et al. (2006). British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Medicine, 7(8), 487-503.
8. Lodwick, R.K., Smith, C.J., Youle, M., Lampe, F.C., Tyrer, M., Bhagani, S., et al. (2008). Stability of antiretroviral regimens in patients with viral suppression. AIDS, 22(9), 1039-1046.
9. Lubeck, D.P., Bennett, C.L., Mazonson, P.D., Fifer, S.K., & Fries, J.F. (1993). Quality of life and health service use among HIV-infected patients with chronic diarrhea. Journal of Acquired Immune Deficiency Syndrome, 6(5), 478-484.
10. Mocroft, A., Ledergerber, B., Katlama, C., Kirk, O., Reiss, P., d'Arminio, M.A., et al. (2003). Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet, 362(9377), 22-29.
11. Molina, J.M., Andrade-Villanueva, J., Echevarria, J., Chetchotisakd, P., Corral, J., David, N., et al. (2008a, October 25-26). Atazanavir/ritonavir vs lopinavir/ ritonavir in antiretroviral naive HIV-1 infected patients: CASTLE 96 week efficacy and safety. Presented at 48th Annual ICAAC/IDSA Annual Meeting, Washington, DC.
12. Molina, J.M., Andrade-Villanueva, J., Echevarria, J., Chetchotisakd, P., Corral, J., David, N., et al. (2008b). Once-daily atazanavir/ritonavir versus twicedaily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet, 372(9639), 646-655.
13. Munakata, J., Benner, J.S., Becker, S., Dezii, C.M., Hazard, E.H., & Tierce, J.C. (2006). Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus. Medical Care, 44(10), 893-899.
14. O'Brien, M.E., Clark, R.A., Besch, C.L., Myers, L., & Kissinger, P. (2003). Patterns and correlates of discontinuation of the initial HAARTregimen in an urban outpatient cohort. Journal of Acquired Immune Deficiency Syndrome, 34(4), 407-414.
15. Ortiz, R., DeJesus, E., Khanlou, H., Voronin, E., van Lunzen, J., Andrade-Villanueva, J., et al. (2008). Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS, 22(12), 1389-1397.
16. Park-Wyllie, L.Y., Strike, C.S., Antoniou, T., & Bayoumi, A.M. (2007). Adverse quality of life consequences of antiretroviral medications. AIDS Care, 19(2), 252-257.
17. Rachlis, A., Gill, J., Baril, J.G., LeBlanc, R.P., Trottier, B., MacLeod, J., et al. (2005). Effectiveness of step-wise intervention plan for managing nelfinavir-associated diarrhea: A pilot study. HIV Clinical Trials, 6(4), 203- 212.
18. Schiller, D.S. (2004). Identification, management, and prevention of adverse effects associated with highly active antiretroviral therapy. American Journal of Health System Pharmacy, 61(23), 2507-2522.
19. Sherman, D.S., & Fish, D.N. (2000). Management of protease inhibitor-associated diarrhea. Clinical Infectious Diseases, 30(6), 908-914.
20. Snijders, F., de Boer, J.B., Steenbergen, B., Schouten, M., Danner, S.A., & van Dam, F.S. (1998). Impact of diarrhoea and faecal incontinence on the daily life of HIV-infected patients. AIDS Care, 10(5), 629-637.
21. Torti, C., & Frank, I. (2008). A king in the CASTLE? Optimum initial HIV protease inhibitor. Lancet, 372(9639), 604-606.
22. Uy, J., Yang, R., Thiry, A., Absalon, J., Farajallah, A., Maa, J., et al. (2008, November 9-13). Efficacy and safety by baseline HIV RNA and CD4 count in treatment-naïve patients treated with atazanavir/RTV and lopinavir/RTV in the CASTLE study. Presented at Ninth International Congress on Drug Therapy in HIV Infection, Glasgow, UK.
23. Vo, T.T., Ledergerber, B., Keiser, O., Hirschel, B., Furrer, H., Battegay, M., et al. (2008). Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 197(12), 1685-1694.
24. Watson, A., Samore, M.H., & Wanke, C.A. (1996). Diarrhea and quality of life in ambulatory HIVinfected patients. Digestive Disease and Science, 41(9), 1794-1800.